ALBALIVA 49mg / 51mg film-coated tablets medication leaflet

C09DX04 • sacubitril + valsartan • Cardiovascular system | Angiotensin II receptor blockers (ARBs), combinations | Angiotensin ii receptor blockers (arbs), other combinations

Sacubitril+valsartan is a combination medication used in the treatment of chronic heart failure with reduced ejection fraction. Sacubitril is a neprilysin inhibitor, an enzyme that degrades natriuretic peptides, bradykinin, and other vasodilatory substances. By inhibiting neprilysin, sacubitril increases the levels of these substances, improving cardiac function. Valsartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure and reduces the workload on the heart.

This combination is taken orally, usually twice daily, and is indicated for patients with chronic heart failure to reduce the risk of hospitalization and cardiovascular mortality. It is considered an advanced therapy in heart failure management.

Common side effects include hypotension, hyperkalemia, dizziness, and renal impairment. In rare cases, severe adverse reactions such as angioedema may occur. Regular monitoring of blood pressure, renal function, and potassium levels is essential.

Sacubitril+valsartan represents an innovation in heart failure treatment, providing significant benefits in reducing symptoms and improving patients' quality of life.